Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.
about
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsRole of B cells in tolerance inductionPolyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.Desensitization: Overcoming the Immunologic Barriers to TransplantationKidney transplantation in highly sensitized patients.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Strategies to overcome the ABO barrier in kidney transplantation.The effectiveness and safety of rituximab as induction therapy in ABO-compatible non-sensitized renal transplantation: a systematic review and meta-analysis of randomized controlled trials.Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.Use of polyclonal/monoclonal antibody therapies in transplantation.Absence of Intragraft B Cells in Rejection Biopsies After Rituximab Induction Therapy: Consequences for Clinical Outcome.A Paradigm Shift on the Question of B Cells in Transplantation? Recent Insights on Regulating the Alloresponse.A comparison of three induction therapies on patients with delayed graft function after kidney transplantation.Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion.Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease.Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment.Preemptive CD20+ B cell Depletion Attenuates Cardiac Allograft Vasculopathy in CD154-Treated Monkeys.The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation.ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management.Desensitisation strategies in high-risk children before kidney transplantation.Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients.B cell depletion at induction--making bad immunological memory fade?The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q26774993-3DC25D9D-A7FC-4AF7-ABF7-5219211821D2Q26824451-CA665FE6-C93A-4565-AE5B-7E47CCAE702AQ30239091-144DA860-8136-43B6-A865-49D6FFF70081Q30397952-858FC06C-BF0C-43D0-882F-61B8BD714E09Q38455229-F02BE632-30C5-4FC5-926A-A29F65BB8A72Q38530254-46E8093B-ED3A-4BEE-9BBC-AEE368D65A15Q38577657-49AA2A79-3A68-4A5F-9014-85E0346C4FA6Q38580399-D7572DFA-6701-4729-8179-4C8CB3008D8BQ38614123-37362877-EC4F-47AC-A8C0-9B947791EE57Q38769922-89C69E69-2279-49F9-B8A1-72F31CEED8F9Q38839087-CE5C600E-B4B2-4FDC-AB3E-EDE85459C000Q39140007-438A2301-325B-4D27-9F2D-C8EB600AEE82Q39541551-67730A77-786F-4833-9E71-8DF58D7E1CF1Q39708039-542948A4-637A-4719-BE01-DE95DDFFA468Q40075357-F537D1E0-C534-4F4B-8BAB-39E795367E2AQ40100407-A5521639-7572-4692-91D0-EA9EF6040D3BQ40630490-A67FC345-C40D-4778-BEB1-A497DF83FA7FQ40670409-646480D8-81D6-43DC-B0A2-E50100E1C8B6Q40915460-EFB07FFB-F8F9-4B0E-B808-877FDC441592Q47563660-386A796E-CFCA-455D-9760-740937E427DEQ48185108-5AA28841-42E2-4ED8-A573-33C8E82CFC6DQ50756723-B328F263-6D03-447C-AB06-149317DF3EA4Q53186858-54953872-35DF-41F9-B58B-971909689692Q58805821-922BC4EB-9E97-4C6B-BFB2-384FC53BE15B
P2860
Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Rituximab as induction therapy ...... study of efficacy and safety.
@en
type
label
Rituximab as induction therapy ...... study of efficacy and safety.
@en
prefLabel
Rituximab as induction therapy ...... study of efficacy and safety.
@en
P2093
P2860
P356
P1476
Rituximab as induction therapy ...... d study of efficacy and safety
@en
P2093
E J Steenbergen
H J P M Koenen
L B Hilbrands
M W F van den Hoogen
S Florquin
P2860
P304
P356
10.1111/AJT.13052
P407
P577
2015-02-01T00:00:00Z